Find information on thousands of medical conditions and prescription drugs.

Methoxsalen

Methoxsalen (marketed under the trade name oxsoralen) is a drug used to treat psoriasis in conjunction with exposing the skin to sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, allegedly clearing up the disease. The dosage comes in 10mg tablets, which are taken in the amount of 30mg 75 minutes before a PUVA light treatment. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Methoxsalen
OCL
Octabenzone
Octanoic acid
Octopamine
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Omeprazole
Oncovin
Ondansetron
Opium
Oratane
Oretic
Orinase
Orlistat
Ornidazole
Ornithine
Orotic acid
Orphenadrine
Ortho Evra
Oruvail
Ovcon
Ovral
Ovrette
Oxaliplatin
Oxamniquine
Oxandrin
Oxandrolone
Oxaprozin
Oxazepam
Oxcarbazepine
Oxetine
Oxibendazole
Oxiracetam
Oxprenolol
Oxybenzone
Oxybuprocaine
Oxycodone
Oxycodone
Oxymetazoline
Oxymetholone
Oxymorphone
Oxytetracycline
Oxytocin
P
Q
R
S
T
U
V
W
X
Y
Z

Patients with high blood pressure or a history of liver problems are at risk for inflammation and irreparable damage to both liver and skin. The eyes must be protected from UVA radiation. Side effects include nausea, headaches, dizziness, and in rare cases insomnia.

Read more at Wikipedia.org


[List your site here Free!]


Chemotherapy and photodynamic therapy in treating patients with cutaneous T-cell lymphoma - Clinical Trial Review
From Journal of Drugs in Dermatology, 6/1/03

Sponsored by: Millennix

Rationale: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Photosensitizing drugs, such as methoxsalen, are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. Combining chemotherapy with photodynamic therapy may be an effective treatment for cutaneous T-cell lymphoma.

Purpose: Randomized phase II trial to study the effectiveness of combining different doses of bexarotene with photodynamic therapy in treating patients who have stage IB or stage IIA cutaneous T-cell lymphoma.

Study Type: Interventional

Study Design: Treatment

Official Title: Phase II Randomized Study of Bexarotene and Ultraviolet A Light Therapy with Methoxsalen (PUVA) in Patients with Stage IB or IIA Cutaneous T-Cell Lymphoma

This is a randomized, open-label, multicenter study. Patients are randomized to one of two treatment arms:

* Arm I: Patients receive a lower dose of oral bexarotene once daily on weeks 1-26. Patients also receive ultraviolet A light therapy with oral methoxsalen 3 times weekly on weeks 2-26;

* Arm II: Patients receive a higher dose of oral bexarotene once daily on weeks 1-26. Patients also receive ultraviolet A light therapy as in arm I. Patients are followed at 4 weeks.

Ages Eligible for Study: 18 years and above

Genders Eligible for Study: Both

Criteria

* Histologically confirmed cutaneous T-cell lymphoma within the past year

* Stage IB or IIA disease

* No prior diagnosis more advanced than stage IIA disease

A total of 100 patients (50 per treatment arm) will be accrued for this study.

Contact: Study Chair: Joan Guitart, MD

Northwestern University Medical Center

Chicago, Illinois, 60611, United States

Tel: 312-695-1413

COPYRIGHT 2003 Journal of Drugs in Dermatology
COPYRIGHT 2004 Gale Group

Return to Methoxsalen
Home Contact Resources Exchange Links ebay